Zhuhai Trinomab Pharmaceutical Co., Ltd. (SHA:688806)

Market Cap	10.98B
Revenue (ttm)	75.98M +1,650.9%
Net Income	-520.98M
EPS	-1.33
Shares Out	460.55M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,030,638
Open	24.35
Previous Close	23.84
Day's Range	24.20 - 27.30
52-Week Range	14.46 - 52.52
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About SHA:688806

Zhuhai Trinomab Pharmaceutical Co., Ltd., a biopharmaceutical company, researches, develops, and commercializes therapeutics for infectious diseases and pain-related or autoimmune disorders. The company’s product includes Siltartoxatug Injection (TNM002), a recombinant anti-tetanus toxin monoclonal antibody that neutralizes the toxic effects that target the human neural system. The company was founded in 2015 and is based in Zhuhai, China.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Employees: 843
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688806

Financial Performance

In 2025, SHA:688806's revenue was 51.22 million, an increase of 240.23% compared to the previous year's 15.06 million. Losses were -601.32 million, 16.8% more than in 2024.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 4, 2026

Data Sources Report a data error